December 2020 - Page 8 of 32

TuesdayDec 22, 2020 2:54 pm

QualityStocksNewsBreaks – Why RYAH Group Inc. Is ‘One to Watch’

RYAH Group is a leading digital health care analytics and technology company with a mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments. Through its IoT dose-measuring devices and AI analytics, RYAH is focused on expanding understanding of the value of devices combined with data to positively impact the future treatment of patients for various medical conditions. A recent article discussing the company reads, “Since it began developing and commercializing its smart inhaler solution in 2018, the company has evolved a complete IoT device and data analytics platform that includes multiple delivery mechanisms, designed…

TuesdayDec 22, 2020 2:39 pm

QualityStocksNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Takes Game-Changing Visualization Method to the Next Level

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is at the forefront of change in its focus to establish a new standard of care in visualizing cancer. Minimally invasive surgery (“MIS”) using white light to illuminate tumor growth is the current standard of care for bladder cancer. This method is highly effective for visualizing cancerous tumors that protrude above the bladder’s wall. However, due to the difficulty in distinguishing flat tumors from normal tissue, it is nearly impossible to visualize the margins of the tumor under current standards. Game-changing to the industry has been the introduction of blue…

TuesdayDec 22, 2020 2:28 pm

QualityStocksNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Aims to Identify Best Delivery Method for Lead Drug Candidate

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, recently submitted a protocol amendment request to the U.S. Food and Drug Administration (“FDA”). Approval of the amendment will allow AzurRx to modify its current Phase 2b OPTION 2 trial of MS1819 in cystic fibrosis (“CF”) patients to add a study arm that uses immediate release capsules (https://ibn.fm/SxH8F). The existing study arm uses delayed release capsules, so the expansion will allow AzurRx to compare data from both arms to determine the best delivery method for its lead product, an exocrine pancreatic…

TuesdayDec 22, 2020 1:53 pm

QualityStocksNewsBreaks – SRAX Inc. (NASDAQ: SRAX) Poised in Convergence of Digital Technologies, Engagement

SRAX (NASDAQ: SRAX), focused on unlocking data and insights through its software-as-a-service (“Saas”) platform, Sequire, is emerging as a leader within the investor intelligence field. Launched as a stand-alone platform in early 2020, Sequire has amassed over 1 million investors and traders and has attracted over 91 publicly listed companies as subscribers. The explosion in growth is largely driven by Sequire’s extensive range of services and as companies have increasingly sought to adopt digital technology and the data generated from such mediums as a way of improving their engagement with customers and stakeholders alike. A recent article discussing this reads,…

TuesdayDec 22, 2020 1:21 pm

QualityStocksNewsBreaks – TPT Global Tech Inc. (TPTW) Announces Launch of ‘QuikLAB’ and ‘QuikPASS’ Apps

TPT Global Tech (OTC: TPTW), a provider of telecommunications, medical technology, media content for domestic and international syndication as well as technology solutions, today announced the release of two new products and services for use at its TPT Med Tech division. These include its "QuikLAB" App, designed for use in monitoring patient testing and vaccination history, and its "QuikPASS" Mobile App. QuikPASS is designed to allow entrance to any facility or country based on patient test and vaccination results on a real-time basis worldwide. The QuikPASS App will be offered free of charge to U.S. and international consumer markets. TPT…

TuesdayDec 22, 2020 12:58 pm

QualityStocksNewsBreaks – PowerBand Solutions Inc. (TSX.V: PBX) (OTCQB: PWWBF) (FRA: 1ZVA) Enters Agreement with Two Auto Companies to Revolutionize Buying, Leasing Experience

PowerBand Solutions’ (TSX.V: PBX) (OTCQB: PWWBF) (FRA: 1ZVA) has joined forces with two other companies to revolutionize the auto-buying experience. The three companies — PowerBand, CB Auto Group Inc. and D&P Holdings Inc. — have entered into definitive agreements to provide millions of union and affinity group members with an unparalleled group buying power experience; the service, which is designed to provide information so members can be smarter auto shoppers, also allows them to purchase autos using their smartphones, tablets or computer. Beginning Q1 2021, PowerBand’s virtual transaction platform DRIVRZ(TM) website will be available to more than 70 million members of…

TuesdayDec 22, 2020 12:45 pm

QualityStocksNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Announces Completion of Patient Enrollment for Study of Cannabidiol Lotion for Eczema Treatment

Jupiter Wellness (NASDAQ: JUPW), a leading developer of cannabidiol (“CBD”)-based medical therapeutics and wellness products, has completed patient enrollment in its upcoming clinical study of JW-100, its proprietary cannabidiol lotion formulation for the treatment of atopic dermatitis, or eczema. The study is designed to investigate the efficacy and safety of JW-100. JUPW enrolled 66 patients for the multi-center, double-blinded, placebo-controlled trial. Study participants will be randomly selected to receive one of three topical formulations, including a placebo, at least twice daily. Data from the study is expected in Q1 2021. "We are eager to see the results of this trial,…

TuesdayDec 22, 2020 12:27 pm

QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Reaches Another Significant Milestone with Scaled-up Production of Clinical-Grade REQORSA(TM)

Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, has announced its completion of the manufacturing scale-up of REQORSA(TM) immunogene therapy. Subject to satisfactory completion of final testing currently underway, the clinical-grade production is intended to supply Genprex’s upcoming Acclaim-1 and Acclaim-2 clinical trials for the treatment of non-small cell lung cancer. The company recently announced the successful manufacturing technology transfer to commercial contract development and manufacturing organizations (“CDMOs”) as well as the successful engineering run of REQORSA, which passed all testing specifications. “The scaled-up production of clinical-grade REQORSA is yet another significant manufacturing milestone…

TuesdayDec 22, 2020 12:16 pm

QualityStocksNewsBreaks – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Applauds Bipartisan Appropriation of Funds for US Uranium Reserve

Energy Fuels (NYSE American: UUUU) (TSX: EFR), the largest uranium miner in the U.S., applauds the bipartisan, bicameral launch of the U.S. uranium reserve, as $75 million of funding was included in the omnibus appropriation bill. The bill, passed last night by both houses of Congress, is expected to be sent to the President for signature in the coming days. One of the main recommendations of the U.S. Nuclear Fuel Working Group, directed to make recommendations on securing the domestic capacity to produce uranium and nuclear fuel, was to appropriate funding for a U.S. uranium reserve. This key funding opens…

TuesdayDec 22, 2020 12:07 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Moving Forward with Clinical Trials in 2021 after Receiving FDA Approval for IND for Berubicin

The company is scheduled to conduct three clinical trials in 2021 for Berubicin – two Phase II and the first-ever Phase I in pediatric patients FDA modified the trial design to designate overall survival as the trial’s primary endpoint The market for brain tumor therapies is expected to grow at a CAGR of 10% and reach an estimated $1.6 billion in 2025 CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, announced that it obtained the Food and Drug Administration’s Investigational New Drug…

Site Search

Company Search

Month: December 2020